Share this article
TARRYTOWN, N.Y., May 19, 2021 /PRNewswire/
Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanoma
Regeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology portfolio
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN) today announced the company will share a range of presentations for its PD-1 inhibitor Libtayo
® (cemiplimab-rwlc) and broader oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, taking place virtually. Presentations include new clinical data and in-depth analyses on the impact of Libtayo in several advanced cancers, including non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and melanoma.
iBerkshires com - The Berkshires online guide to events, news and Berkshire County community information iberkshires.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iberkshires.com Daily Mail and Mail on Sunday newspapers.